8-K current report · filed Aug 12, 2026

Definium Therapeutics, Inc. (DFTX) 8-K Current Report: August 12, 2026

Item EX-99.1Item EX-99.2Item 8.01Item 7.01DFTX overview

Short answer

Definium Therapeutics, Inc. (DFTX) filed an 8-K current report with the SEC on August 12, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Positive topline Phase 3 Voyage data for DT120 ODT in generalized anxiety disorder.

Definium Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Positive topline Phase 3 Voyage data for DT120 ODT in generalized anxiety disorder
  • Results represent a major clinical milestone, potentially supporting regulatory submission and commercialization plans
  • Full efficacy and safety findings available in Exhibit 99.1, critical for assessing approval prospects and valuation impact

Item 8.01 · Other Events

  • Presentation announces Voyage topline data, making the program’s clinical readout material to Definium’s valuation
  • Exhibit 99.2 contains the detailed data and supporting presentation for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Phase 3 Voyage met primary and all key secondary endpoints in 214 GAD patients, materially advancing DT120 ODT toward potential approval
  • HAM-A improvement at Week 12: -11.6 DT120 versus -6.2 placebo, placebo-adjusted difference 5.4 points, p<0.0001, Cohen’s d=0.81
  • Efficacy emerged by Day 2 and persisted through Week 12, supporting DT120’s potential for rapid and durable symptom relief
  • Week 12 response rate 43% versus 16% placebo; remission rate 14% versus 4%
  • Generally well tolerated with no new safety signals; 92% met end-of-session criteria by hour 8, while Panorama results are expected in September

Item EX-99.2 · Exhibit EX-99.2

  • Phase 3 Voyage met all primary and key secondary endpoints in 214-patient GAD study, strengthening DT120 ODT’s pivotal efficacy profile
  • Week 12 HAM-A improvement versus placebo: 5.4 points, p<0.0001; week 1 advantage 7.7 points, p<0.0001
  • Response rate 43% versus 16% placebo, with remission 14% versus 4% at week 12
  • DT120 ODT generally tolerated, but treatment-emergent adverse events affected 99% versus 69% for placebo
  • Average session clearance 6.4 hours, with 92% cleared by hour 8, supporting potential outpatient treatment logistics

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Definium Therapeutics, Inc. 8-K filings

Get the next DFTX 8-K as it lands

Follow DFTX for push alerts, or ask the research agent what this filing means.